Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, an estimated 3.4 million people in the United States had active epilepsy, including about 3 million adults and 470,000 children. Epilepsy is the…
UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B. The deal marks a strategic expansion into regenerative medicine and advanced therapies,…
UCB completes acquisition of Neurona Therapeutics (Brussels, 2 June 2026), including lead asset rezanecel, an investigational Phase 1/2 neuronal cell therapy…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
UCB completed its acquisition of Neurona Therapeutics on 2 June 2026 (announced 17-21 April 2026) for up to $1.15B ($650M upfront + up to $500M milestones), adding lead asset rezanecel (formerly NRTX-1001), a Phase 1/2 allogeneic GABAergic interneuron cell therapy delivered by a single stereotactic hippocampal injection for drug-resistant mesial temporal lobe epilepsy. The deal moves UCB into regenerative medicine atop its long-standing epilepsy franchise (Keppra, Vimpat, Briviact, Fintepla). Rezanecel remains investigational and is not FDA-approved.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Neurona Therapeutics, Inc. (this deal) | 2026 | $1.1B | — |
| UCB S.A. / Candid Therapeutics, Inc. | 2026 | $2.2B | — |
| UCB S.A. / Ra Pharmaceuticals, Inc. | 2019 | $2.1B | — |
| UCB S.A. / Zogenix Inc. | 2022 | $1.9B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2026 deals · UCB S.A. deals · Neurology deals